Recent Finacing
Recent Raise
Corteria Pharmaceuticals develops subcutaneous CRF2 agonists and an AVP‑neutralizing monoclonal antibody for specific heart-failure subpopulations, advancing a lead Worsening Heart Failure asset toward clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Corteria Pharmaceuticals.
